Tezepelumab Reduced Exacerbations in Severe, Uncontrolled Asthma, Regardless of Number of Additional Controller Medications
October 18, 2022

CHEST 2022. Tezepelumab significantly reduced AAER and improved lung function in patients taking 1, 2, or ≥3 long-acting β-agonists in addition to ICS.

Simple Primary Care Screening Tool Predicts Asthma Diagnosis in Preschoolers
October 07, 2022

The noninvasive, easily administered tool was able to predict at age 3 years children who would be diagnosed with asthma at age 5 years.

Inhaler Education with Teach-to-Goal Methods Improved Technique Among Older Adults with Asthma, COPD
August 02, 2022

Additional research into tailored metered-dose inhaler education is needed, according to authors of a recent study.

Continuity of Care for Asthma, COPD Patients Could Improve Survival, Cut Costs
July 08, 2022

When asthma and COPD patients have a continuous relationship with a single provider, ED visits/hospitalizations go down, survival goes up, finds a new systematic review.

Patients with Moderate or Severe Asthma Benefit from High-intensity Interval Training, Study Finds
June 20, 2022

New findings suggest that HIIT may be an effective aerobic exercise option for asthma patients.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
May 20, 2022

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Review of Biologic Treatments for Asthma Finds Inconsistent Effects on Airway Hyperresponsiveness
May 19, 2022

ATS 2022: Findings from a literature review provide insight into the mechanisms of airway hyperresponsiveness in asthma.

Tezepelumab Reduces Asthma Exacerbations by More than Half, Reports NAVIGATOR Study Author
May 19, 2022

Njira Lugogo, MD, sat down with Patient Care Online to discuss findings from the prespecified exploratory analysis of the NAVIGATOR study that she presented at ATS 2022.

Real-world Data Showed Mepolizumab Reduced Exacerbations, Oral Corticosteroid Use in Adults with Severe Asthma
May 18, 2022

ATS 2022: Mepolizumab was effective in reducing asthma exacerbations and oral corticosteroid use in real-world clinical practice, according to new research.

Majority of Asthma Patients Prescribed Dupilumab vs Other Biologics as Initial Rx, According to Extensive Real-world Analysis
May 18, 2022

ATS 2022: Dupilumab is often the first biologic agent prescribed for moderate-to-severe asthma according to analysis of a US database comprising more than 100 million patients.